CTSO has been the topic of a number of other research reports. ValuEngine downgraded shares of Cytosorbents from a hold rating to a sell rating in a report on Friday, December 15th. B. Riley restated a buy rating and set a $11.25 target price on shares of Cytosorbents in a research note on Thursday, January 25th. Finally, HC Wainwright restated a buy rating and set a $14.00 target price on shares of Cytosorbents in a research note on Tuesday, January 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Cytosorbents presently has an average rating of Buy and an average target price of $11.05.
Cytosorbents (NASDAQ CTSO) traded down $0.15 on Friday, hitting $7.75. 317,274 shares of the company were exchanged, compared to its average volume of 209,704. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36. The stock has a market capitalization of $232.82, a P/E ratio of -27.68 and a beta of -0.17. Cytosorbents has a one year low of $3.30 and a one year high of $8.10.
Several institutional investors have recently added to or reduced their stakes in CTSO. Skylands Capital LLC raised its position in shares of Cytosorbents by 45.1% during the fourth quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after buying an additional 225,558 shares during the last quarter. B. Riley Financial Inc. bought a new stake in shares of Cytosorbents during the fourth quarter valued at approximately $992,000. Millennium Management LLC increased its position in Cytosorbents by 297.8% in the fourth quarter. Millennium Management LLC now owns 163,977 shares of the medical research company’s stock worth $1,066,000 after purchasing an additional 122,760 shares during the last quarter. BlueCrest Capital Management Ltd bought a new stake in Cytosorbents in the fourth quarter worth $396,000. Finally, Wealthcare Advisory Partners LLC bought a new stake in Cytosorbents in the third quarter worth $365,000. Hedge funds and other institutional investors own 11.13% of the company’s stock.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.